Abstract | PURPOSE: METHODS: Xenografts evaluated were derived from childhood high-grade gliomas (D-212 MG, D-456 MG), adult high-grade gliomas (D-54 MG, D-245 MG), medulloblastomas (D-341 MED, D-487 MED), and ependymomas (D-528 EP, D-612 EP), as well as sublines with demonstrated resistance to procarbazine (D-245 MG (PR)) and busulfan (D-456 (BR)). In replicate experiments, karenitecin was given at 1.0 mg/kg per dose via intraperitoneal injection for a period of 10 consecutive days, which is the dosage lethal to 10% of treated animals. RESULTS:
Karenitecin produced statistically significant (P < or = 0.001) growth delays in all subcutaneous xenografts tested, including the sublines resistant to procarbazine and busulfan. Growth delays ranged from 12.1 days in D-456 MG (BR) to 90+ days in D-212 MG and D-341 MED. Karenitecin also produced statistically significant (P < or = 0.001) increases in survival of animals bearing D-341 MED intracranial xenografts (69% increase) and those bearing D-456 MG xenografts (62% increase). CONCLUSION: These preclinical studies confirm that karenitecin is active against human central nervous system xenografts and should undergo clinical evaluation in patients with malignant central nervous system tumors.
|
Authors | S T Keir, F Hausheer, A A Lawless, D D Bigner, H S Friedman |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 48
Issue 1
Pg. 83-7
(Jul 2001)
ISSN: 0344-5704 [Print] Germany |
PMID | 11488529
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- cositecan
- Irinotecan
- Camptothecin
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Brain Neoplasms
(drug therapy)
- Camptothecin
(analogs & derivatives, pharmacology, therapeutic use)
- Female
- Humans
- Irinotecan
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neoplasm Transplantation
- Transplantation, Heterologous
|